A synthetic drug being developed for the treatment of life-threatening infections has the potential to become the first new treatment for antibiotic-resistant superbugs in more than 50 years, the New York Times reports.
According to the Pew Charitable Trusts, the drug, called RECCE 327, is the only synthetic polymer and drug candidate in development that has been "approved by the FDA for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms."
It has also been designated a "Qualified Infectious Disease Product" under the Generating Antibiotic Initiatives Now (GAIN) Act and given 10 years of market exclusivity post approval by the FDA.
But it's not yet approved for use in humans.
"The threat of antibiotic resistance is greater now than ever, and commercial-academic partnerships are crucial to advance antibiotic discovery," Andrew Steer, theme director of infection, immunity, and global health at Murdoch Children's Research Institute in Australia, says in a press release.
"The synergy between our organizations will undoubtedly lead to ground-breaking discoveries that have the potential to transform the landscape of infectious disease treatment."
Recce Pharmaceuticals, which is based in Australia, says its synthetic polymer anti-infectives have the potential to
Read the Entire Article
A customized collection of news from foundations from around the Web.
First Enterprise Business Agency (FEBA), a Nottingham-based business support organization, is a contender for two categories at the first Citi Microentrepreneurship Awards to be held this coming February.